Antliabio 113
Alternative Names: Antliabio-113Latest Information Update: 26 Apr 2023
At a glance
- Originator Antlia Bioscience
- Class Antiasthmatics; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Asthma
Most Recent Events
- 10 Apr 2023 XL-protein’s proprietary PASylation® technology has a patent protection worldwide including in Europe, in the US, Japan as well as several other countries and territories 2023 (Antlia Bioscience pipeline, April 2023)
- 10 Apr 2023 Preclinical trials in Asthma in USA (Parenteral), prior to April 2023 (Antlia Bioscience pipeline, April 2023).